Non-interventional study of the safety and effectiveness of fluticasone propionate/formoterol fumarate in real-world asthma management

Therapeutic Advances in Respiratory Disease
Vibeke BackerTim Overend

Abstract

In recognition of the value of long-term real-world data, a postauthorization safety study of the inhaled corticosteroid (ICS) fluticasone propionate and long-acting β2-agonist (LABA) formoterol fumarate (fluticasone/formoterol; Flutiform®) was conducted. This was a 12-month observational study of outpatients with asthma aged ⩾ 12 years in eight European countries. Patients were prescribed fluticasone/formoterol according to the licensed indication, and independently of their subsequent enrolment in the study. They were then treated according to local standard practice. The study objectives were to evaluate the safety and effectiveness of fluticasone/formoterol under real-world conditions. The safety population for this study comprised 2539 patients (mean age 47.7 years; 94.3% aged ⩾ 18 years; 63.4% female). Most patients (1538/2539, 60.6%) had switched to fluticasone/formoterol from another ICS/LABA, primarily due to lack of efficacy (1150/2539, 45.3%). Three quarters (77.4%) of patients were treated for 12 months, and 80.6% continued fluticasone/formoterol treatment after the study. Adverse events (AEs) occurred in 60.0% patients, and 10.2% had AEs considered possibly related to fluticasone/formoterol [most commonly asthma ex...Continue Reading

References

May 1, 1996·American Journal of Respiratory and Critical Care Medicine·A WoolcockL A Jacques
Mar 19, 2002·The Journal of Allergy and Clinical Immunology·Stanley J SzeflerUNKNOWN Asthma Clinical Research Network of the National Heart Lung, and Blood Institute
Feb 27, 2003·The Medical Journal of Australia·Heather Powell, Peter G Gibson
Sep 5, 2006·The Journal of Allergy and Clinical Immunology·Claudine MarceauLucie Blais
Mar 3, 2007·The European Respiratory Journal·P J Barnes
Jan 5, 2011·Respiratory Medicine·Anna Bodzenta-LukaszykHeikki Mansikka
Oct 5, 2012·The New England Journal of Medicine·Roderick J LittleHal Stern
Oct 27, 2012·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Adel H Mansur, Kirsten Kaiser
Oct 30, 2012·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Anna Bodzenta-LukaszykSanjeeva Dissanayake
Feb 25, 2014·Annals of the American Thoracic Society·Gary W K WongJerry Krishnan
Feb 25, 2014·Annals of the American Thoracic Society·Nicolas RocheUNKNOWN Respiratory Effectiveness Group
Mar 8, 2014·Thorax·John P NewAshley Woodcock
Aug 26, 2015·Breathe·David PriceAlison Chisholm
Apr 23, 2016·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Alberto PapiSanjeeva Dissanayake
Mar 30, 2017·The Journal of Allergy and Clinical Immunology. in Practice·Omar S UsmaniDavid Price

❮ Previous
Next ❯

Software Mentioned

Flutiform
ffAiRNeSS

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.